Irritable Bowel Syndrome

From the impact of Humira biosimilars flooding the U.S. market to shifting trends in colorectal cancer demographics, Healio has asked experts the big questions to stay abreast of the current hot topics in gastroenterology and hepatology.

In a Healio video exclusive, Edward V. Loftus Jr., MD, highlighted the growing recognition that diet, specifically tailored nutrition interventions, can play a crucial role in the management of several gastrointestinal disorders.

A diagnosis of irritable bowel syndrome based on Rome IV criteria was “safe and durable,” with only 1% of patients diagnosed with a different gastrointestinal disease after rereferral and reinvestigation for ongoing IBS symptoms.

In my more than 30-year career as a registered dietitian in gastroenterology, it has been exciting to see the role of dietitians in gastrointestinal conditions become validated and expanded upon, most markedly over the past 10 years.

Irritable bowel syndrome is a dysfunction in the communication pathway between the gut and the brain, which contributes to symptoms such as gas, bloating, abdominal pain, diarrhea, constipation and mixed bowel habits.

A U.S. District Court judge in Delaware has denied Norwich Pharmaceuticals’ motion to modify the court’s final judgment, which blocks the FDA from approving their 550 mg rifaximin generic until Oct. 2, 2029.

CHICAGO — Digital gut-directed hypnotherapy resulted in greater improvement in abdominal pain and stool symptoms in patients with irritable bowel syndrome compared with digital muscle relaxation, according to research.

Anthony Lembo, MD, Director of Research for Cleveland Clinic's Digestive Disease & Surgery Institute, discusses the diagnostic process for patients presenting with constipation; approaching management of patients with IBS with constipation and chronic idiopathic constipation; treatment options and recent therapeutic advances; health disparities; and important challenges of care.

More than half of the respondents in Salix Pharmaceutical’s annual patient perspective survey reported waiting at least a year before mentioning their irritable bowel syndrome symptoms to a health care provider.

Infection with SARS-CoV-2 increased the risk for long-term gastrointestinal problems within 1 year, including motility disorders, acute pancreatitis and liver disease, according to a study published in Nature Communications.